Most of the drugs predicted using the DGIDb database are used in hematological cancers and disorders, in line with the findings of the MCODE enrichment analysis, showing the crucial role of platelet degranulation and Interleukin-3, Interleukin-5, and GM-CSF signaling. This evidence concerns the gene IL3 and hematopoietic and lymphoid cell neoplasm.